WaveMan
WaveMan · Company
RLYB · Rallybio Corp
> Search tickers & screens ⌘K
LIVE
← All companies

RLYB Rallybio (RLYB) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001739410
Quote by TradingView
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
19
13F, latest reported quarter
Conversions, 180 days
12
Codes C/M, not in net · $430.5K priced

What the filings say about RLYB

Insiders, 180 days
+$4.2M net bought
2 buyers

Rallybio insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Rallybio Corp insiders bought a net $4.2M of stock across 45 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
ADAR1 Capital Management, LLC
BUY
2026-05-20 SECtraded 2026-05-19
10,000
$139.8K
+8.3%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on May 18, 2026.
  • +18.6% median (+19.2% mean) 90-day return after 3 previous buys.
  • The trade is 1.1% of the 926,152 shares held after it.
  • 1 other insider bought within 30 days.
  • 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider ADAR1 Capital Management, LLC bought about $139.8K of RLYB on May 19, 2026; 1 other insider bought within 30 days and 19 funds added in the latest 13F quarter.
ADAR1 Capital Management, LLC
BUY
2026-05-20 SECtraded 2026-05-19
200
$2.8K
+8.3%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on May 18, 2026.
  • +18.6% median (+19.2% mean) 90-day return after 3 previous buys.
  • The trade is 0.0% of the 926,352 shares held after it.
  • 1 other insider bought within 30 days.
  • 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider ADAR1 Capital Management, LLC bought about $2.8K of RLYB on May 19, 2026; 1 other insider bought within 30 days and 19 funds added in the latest 13F quarter.
ADAR1 Capital Management, LLC
BUY
2026-05-20 SECtraded 2026-05-18
6,009
$84.0K
+8.3%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on May 12, 2026.
  • +18.5% median (+18.5% mean) 90-day return after 2 previous buys.
  • The trade is 0.7% of the 916,152 shares held after it.
  • 1 other insider bought within 30 days.
  • 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider ADAR1 Capital Management, LLC bought about $84.0K of RLYB on May 18, 2026; 1 other insider bought within 30 days and 19 funds added in the latest 13F quarter.
Schneeberger Daniel
BUY
2026-05-15 SEC
200
$2.8K
+18.1%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on May 13, 2026.
  • +13.0% median (+12.9% mean) 90-day return after 3 previous buys.
  • The trade is 0.0% of the 910,143 shares held after it.
  • 1 other insider bought within 30 days.
  • 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Schneeberger Daniel bought about $2.8K of RLYB on May 15, 2026; 1 other insider bought within 30 days and 19 funds added in the latest 13F quarter.
Schneeberger Daniel
BUY
2026-05-15 SEC
100
$1.4K
+18.1%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on May 13, 2026.
  • +13.0% median (+12.9% mean) 90-day return after 3 previous buys.
  • The trade is 0.0% of the 909,943 shares held after it.
  • 1 other insider bought within 30 days.
  • 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Schneeberger Daniel bought about $1.4K of RLYB on May 15, 2026; 1 other insider bought within 30 days and 19 funds added in the latest 13F quarter.
45 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 40 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$4.2M over 180 days
+$4.2M of it by a 10%+ holder
more than 93% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
19 funds bought in last quarter
below 70% of Pharma & Biotech
Revenue
+34.9% year over year
more than 72% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
2.4% of the float short (float per yahoo 2026-10-27) · 7.4 days to cover · settled 2026-10-15
below 75% of Pharma & Biotech
What changed in the last 30 days
Oct 28Insider buying stopped: no purchases in 90 days after 14 in the prior 90
Why it matters
The absence is the signal: 14 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.

Watch RLYB

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+246.9%12M
-10%+80%+169%+259%2025-102025-122026-022026-042026-062026-082026-10 2026-05-04 · Schneeberger Daniel bought $1.6M2026-05-13 · Schneeberger Daniel bought $1.1M2026-05-05 · Schneeberger Daniel bought $491.4K2026-05-11 · ADAR1 Capital Management, LLC bought $350.0K2026-05-11 · ADAR1 Capital Management, LLC bought $278.6K2026-05-19 · ADAR1 Capital Management, LLC bought $139.8K2026-05-18 · ADAR1 Capital Management, LLC bought $84.0K2026-05-11 · ADAR1 Capital Management, LLC bought $71.4K2026-05-13 · Schneeberger Daniel bought $56.3K2026-05-04 · Schneeberger Daniel bought $54.2K2026-05-12 · ADAR1 Capital Management, LLC bought $11.1K2026-02-23 · Lieber Jonathan I sold $4.0K2026-05-15 · Schneeberger Daniel bought $2.8K2026-05-19 · ADAR1 Capital Management, LLC bought $2.8K2026-05-15 · Schneeberger Daniel bought $1.4K
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns RLYB: institutional holders (13F)

13F holdings, latest reported quarter
ADAR1 Capital Management, LLC
926,352 sh
$14.8M
FMR LLC
794,720 sh
$12.7M
VIKING GLOBAL INVESTORS LP
524,347 sh
$8.4M
TPG GP A, LLC
378,551 sh
$6.1M
Nantahala Capital Management, LLC
376,844 sh
$6.0M

Congress trades in RLYB

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

RLYB planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

RLYB mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$189.3K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$12.7K position · as of 2026-06-30
0.0%
Fidelity Series Growth Company Fund
$775.1K position · as of 2026-05-31
0.0%
Fidelity Growth Company Fund
$3.0M position · as of 2026-05-31
0.0%
Fidelity Growth Company K6 Fund
$817.3K position · as of 2026-05-31
0.0%
U.S. MICRO CAP PORTFOLIO
$73.4K position · as of 2026-07-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
3 registered trials, 0 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 1
0 active
1
Phase 2
0 active
1
Not applicable
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $4.2M bought by insiders over 180 days, 19 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

RLYB financials

Revenue growth
+34.9%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$646.0K
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
$26.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
+64.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+61.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-39.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
3.39x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
n/a
no debt line filed
FCF yield
+30.2%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$858.0K$636.0Kn/an/a
Operating income-$33.1M-$60.5M-$78.9M-$67.9M
Net income-$9.0M-$57.8M-$74.6M-$66.7M
EPS (diluted)-1.59-10.61-1.84-2.09
Operating cash flow-$29.8M-$49.3M-$60.3M-$57.3M
Cash$31.4M$13.9M$24.5M$57.0M
SEC XBRL, fiscal years, as known on 2026-10-28

RLYB Stock Sonar score 5/7 axes

Find similar shapesCompare

RLYB ranks highest on insider conviction (87th percentile) and profitability (84th), and lowest on institutional and government (30th), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
84
Inputs
  • Return on equity+64.9% · 95 pct, sector of 545
  • Return on assets+61.1% · 97 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-39.5% · 59 pct, sector of 576
Growth
72
Inputs
  • Revenue growth, YoY+34.9% · 72 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
87
Inputs
  • Net Form 4 buying (codes P and S), 180d$4.2M · 93 pct, sector of 429
  • Insider buyers, 180d2 · 81 pct, sector of 438
Institutional and government
30
Inputs
  • Funds adding, latest quarter19 · 30 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
44
Inputs
  • Short interest, % of float+2.4% · 70 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+19.6% · 18 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

RLYB filings, in plain words

Are Rallybio insiders buying or selling RLYB?

In the 180 days to 2026-10-28, Rallybio insiders were net buyers, a net $4.2M across purchases and sales reported on Form 4, by 2 buyers.

Read the full summary

In the 180 days to 2026-10-28, Rallybio insiders were net buyers of RLYB, a net $4.2M across purchases and sales reported on Form 4 by 2 buyers. Most of that figure, $4.2M, came from a holder of 10% or more rather than an officer or director. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies